Videos 2017
  • 1/30/2017 Organic Acid Applications within the Cosmeceutical Industry 'Chemical PeelsPatricia Brieva Ph.D,  L'Oreal 

     Abstract: Chemical peeling is the application of a chemical agent to the skin, which causes controlled destruction of a part of or the entire epidermis, with or without the dermis, leading to exfoliation and removal of superficial lesions, followed by regeneration of new epidermal and dermal tissues (Khunger, 2008).   The payoff for this type of office procedure is skin that is improved in elasticity, skin-tone, pigmentation, and texture as a result of the regenerated skin.   There are several types of chemical peels generated from variations of organic acid combinations and concentration.  The categories are typically categorized as:  Alpha hydroxy, Betahydroxy, Jessner, Retinoic, Trichloroacetic acid, and Phenol. The focus of this presentation will present the most well-known technologies. However, in addition to acids and concentration levels the efficacy of the chemical agents is dependent on the delivery system, solubility, as well as clinical regimen used and protocol.
    Watch Video

  • 2/15/2017 Gene-corrected fibroblast therapy for recessive dystrophic epidermolysis bullosa using a SIN COL7A1 retroviral vector: Joanna Jackow Ph.D,  Prof. Christiano's lab 

     Abstract: Recessive dystrophic epidermolysis bullosa (RDEB) is a severe genetic skin fragility disorder caused by mutations in the COL7A1 gene encoding type VII collagen, which is the major constituent of anchoring fibrils (AF) at the basement membrane zone (BMZ). Patients with RDEB lack type VII collagen and therefore have severely impaired dermal-epidermal stability. There is currently no specific treatment for RDEB and several approaches using gene, cell and protein-based strategies are being developed. Here, we show that sub-cutaneous injections of gene-corrected RDEB dermal fibroblasts have the potential to reverse the disease phenotype in a human RDEB skin equivalent system in mice. We used a GMP-certified batch of a self-inactivating (SIN) COL7A1 retroviral vector and obtained 50 % transduction efficiency in primary RDEB fibroblasts. Transduced cells showed type VII collagen re-expression, displayed normal proliferative capabilities and viability, and improved adhesion properties in vitro. We provide evidence that intradermal injection of 3 x106 gene-corrected RDEB fibroblasts beneath RDEB skin equivalent grafted onto nude mice allows type VII collagen deposition at the dermal-epidermal junction and anchoring fibrils formation two months after treatment, supporting functional correction in vivo. These results provide a proof of principle that local injection of RDEB fibroblasts corrected with a GMP-certified SIN COL7A1 vector has a therapeutic potential for RDEB patients. 
    Watch Video